Drug Trial Radar · NCT05919264
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
619
Planned (sponsor's estimate)
Start
May 23, 2023
Primary completion
Apr 1, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- Parabilis Medicines, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
Conditions
- Cancer
- Colorectal Cancer
- Solid Tumor
- Locally Advanced Solid Tumor
- Metastatic Cancer
- WNT Pathway
- HCC
- Desmoid
- Microsatellite Stable Colorectal Cancer
- Metastatic Castration-resistant Prostate Cancer
- Familial Adenomatous Polyposis (FAP)
- Endometrial Carcinoma
- Prostate Cancer
- Microsatellite Instability-High Colorectal Cancer
- Adamantinomatous Craniopharyngioma
Interventions
FOG-001Drug
FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days
mFOLFOX-6Drug
mFOLFOX-6 will be administered per the prescribing information in combination with FOG-001
NivolumabDrug
Nivolumab will be administered per the prescribing information in combination with FOG-001
Trifluridine/tipiracilDrug
Trifluridine/tipiracil will be administered per the prescribing information in combination with FOG-001
BevacizumabDrug
Bevacizumab will be administered per the prescribing information in combination with FOG-001
FOG-001Drug
FOG-001 will be administered subcutaneous at assigned doses in continuous cycles of 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- During dose escalation and dose expansion measure incidence and severity of treatment emergent adverse events by CTCAE v5.0Time frame: Through study completion, an average of 10 months
- During dose escalation characterize dose-limiting toxicities (DLTs)Time frame: 1 treatment cycle (28 days)
- During dose expansion describe the Overall Response Rate using RECIST v1.1Time frame: Every 63 days until study completion, approximately 10 months on average
- During dose expansion describe the Disease Control Rate using RECIST v1.1 (Part 2a only)Time frame: 4 months
- During dose expansion describe the PSA30 response rate for participants with prostate cancerTime frame: Baseline, weekly during the first 2 cycles (56 days), bi-weekly during the Cycle 3 (28 days), and then monthly (up to approximately 7 months)
Locations
33 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic
Phoenix, Arizona · Recruiting
Honor Health
Scottsdale, Arizona · Recruiting
Arizona Cancer Center at University of Arizona
Tucson, Arizona · Recruiting
University of California, Los Angeles (UCLA)
Los Angeles, California · Recruiting
Stanford Cancer Institute, Stanford University
Palo Alto, California · Recruiting
University of California San Francisco, Helen Diller Family Comprehensive Cancer Center
San Francisco, California · Recruiting
Sarcoma Oncology Center
Santa Monica, California · Recruiting
University of Colorado
Aurora, Colorado · Recruiting
Yale University School of Medicine
New Haven, Connecticut · Recruiting
Johns Hopkins University, Sibley Memorial Hospital
Washington D.C., District of Columbia · Recruiting
Mayo Clinic
Jacksonville, Florida · Recruiting
Florida Cancer Specialists
Lake Mary, Florida · Terminated
Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
M Health Fairview University of Minnesota Medical Center
Minneapolis, Minnesota · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Duke University
Durham, North Carolina · Recruiting
University Hospitals Cleveland Medical Center, Seidman Cancer Center
Cleveland, Ohio · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Oregon Health and Science University
Portland, Oregon · Recruiting
University of Pennsylvania, Perelman School of Medicine
Philadelphia, Pennsylvania · Recruiting
University of Pittsburgh Medical Center, Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Recruiting
Vanderbilt Ingram Cancer Center
Nashville, Tennessee · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas · Recruiting
University of Virginia
Charlottesville, Virginia · Recruiting
University of Wisconsin, Carbone Cancer Center
Madison, Wisconsin · Recruiting
Integrated Clinical Oncology Network (ICON)
South Brisbane, Queensland, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.